See more : StreamPlay Studio Limited (SP8.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Akili, Inc. (AKLI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akili, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Bank Polska Kasa Opieki S.A. (PEO.WA) Income Statement Analysis – Financial Results
- U10 Corp (ALU10.PA) Income Statement Analysis – Financial Results
- Gratex Industries Limited (GRATEXI.BO) Income Statement Analysis – Financial Results
- Gefran S.p.A. (GE.MI) Income Statement Analysis – Financial Results
- Sweco AB (publ) (SWEC-A.ST) Income Statement Analysis – Financial Results
Akili, Inc. (AKLI)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.akiliinteractive.com
About Akili, Inc.
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.68M | 323.00K | 538.00K | 3.94M | 19.99M |
| Cost of Revenue | 819.00K | 441.00K | 355.00K | 416.00K | 1.34M |
| Gross Profit | 859.00K | -118.00K | 183.00K | 3.52M | 18.64M |
| Gross Profit Ratio | 51.19% | -36.53% | 34.01% | 89.44% | 93.29% |
| Research & Development | 19.93M | 28.86M | 18.23M | 15.42M | 21.27M |
| General & Administrative | 38.84M | 53.84M | 29.78M | 13.54M | 18.88M |
| Selling & Marketing | 6.58M | 7.86M | 12.89M | 0.00 | 0.00 |
| SG&A | 45.42M | 61.70M | 42.67M | 13.54M | 18.88M |
| Other Expenses | 4.04M | 82.73M | 17.00K | 124.00K | 1.03M |
| Operating Expenses | 65.34M | 90.56M | 60.90M | 28.96M | 40.14M |
| Cost & Expenses | 66.16M | 91.00M | 61.26M | 29.38M | 41.48M |
| Interest Income | 0.00 | 1.48M | 8.32K | 333.00K | 157.00K |
| Interest Expense | 2.36M | 1.48M | 465.00K | 333.00K | 157.00K |
| Depreciation & Amortization | 302.00K | 308.00K | 296.00K | 424.00K | 1.29M |
| EBITDA | -60.14M | -88.89M | -60.44M | -25.01M | -20.21M |
| EBITDA Ratio | -3,584.21% | -28,073.37% | -11,231.04% | -634.98% | -101.14% |
| Operating Income | -64.49M | -90.68M | -60.72M | -25.44M | -21.50M |
| Operating Income Ratio | -3,842.97% | -28,073.37% | -11,286.06% | -645.75% | -107.57% |
| Total Other Income/Expenses | 5.05M | 82.73M | -629.00K | -209.00K | 877.00K |
| Income Before Tax | -59.49M | -7.95M | -61.35M | -25.65M | -20.62M |
| Income Before Tax Ratio | -3,545.47% | -2,459.75% | -11,402.97% | -651.05% | -103.18% |
| Income Tax Expense | 53.00K | 19.00K | 482.00K | 1.00K | 13.00K |
| Net Income | -59.49M | -7.96M | -61.83M | -25.65M | -20.63M |
| Net Income Ratio | -3,545.47% | -2,465.63% | -11,492.57% | -651.08% | -103.24% |
| EPS | -0.76 | -0.27 | -1.94 | -0.33 | -0.27 |
| EPS Diluted | -0.76 | -0.27 | -1.94 | -0.33 | -0.27 |
| Weighted Avg Shares Out | 78.20M | 29.88M | 31.89M | 77.86M | 77.86M |
| Weighted Avg Shares Out (Dil) | 78.20M | 29.88M | 31.89M | 77.86M | 77.86M |
Akili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the fourth quarter and full year of 2022 on Tuesday, March 7, 2023 at 4:30...
Akili to Participate in the Cowen 43rd Annual Health Care Conference
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Cowen 43rd Annual Health Care Conference in Boston next month. On March 8, Akili sessions are scheduled for the following times: 8am: Scott Kollins, Akili Chief...
Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference, both happening alongside the J.P. Morgan Healthcare Conference in San Francisco next week. Eddie Martucci, Akili’s Co-Founder and...
5 Hot Penny Stocks Exploding After News This Week
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adolescents label expansion study evaluating the efficacy and safety of EndeavorRxⓇ (AKL-T01) in adolescents ages 13-17 with attention-deficit/hyperactivity disorder (ADHD). The pivotal study achieved...
Akili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer
BOSTON--(BUSINESS WIRE)--Akili, Inc., a leading commercial digital medicine company, today announced the appointment of Scott Kollins, Ph.D., as chief medical officer, effective December 1, 2022. Dr. Kollins will report to Akili’s chief operating officer and join the company’s executive team....
Akili, Inc. (AKLI) Q3 2022 Earnings Call Transcript
Akili, Inc. (NASDAQ:AKLI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Joshua Young - IR Walter Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Santosh Shanbhag - CFO & Treasurer...
Akili Reports Third Quarter 2022 Financial Results and Company Update
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended September 30, 2022, and provided an update on business progress. “We achieved two important milestones this quarter on our path to...
Akili: Developing Video Games To Treat Cognitive Impairments
Akili is developing video games as a means to treat ADHD, depression, and other conditions. The company has approval by the FDA to treat ADHD using its product EndeavorRx. It is also approved to market in "the European Economic Area."
Financial Industry Veteran Mary Hentges Joins Akili’s Board of Directors
BOSTON--(BUSINESS WIRE)--Akili, Inc. (NASDAQ: AKLI), a leading digital medicine company, today announced the appointment of Mary Hentges to the company’s board of directors, effective October 25, 2022. Hentges will serve as chair of the Audit Committee and a member of...
Source: https://incomestatements.info
Category: Stock Reports